Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma

  • Bousquet J
  • Siergiejko Z
  • Świebocka E
 et al. 
  • 60


    Mendeley users who have this article in their library.
  • 80


    Citations of this article.


The physician's global evaluation of treatment effectiveness (GETE) at 16 weeks has been shown to be the most effective assessment of response to omalizumab (XOLAIR®). This randomized, open-label, parallel-group study evaluated the persistency of treatment responder classification in patients receiving omalizumab added to optimized asthma therapy (OAT).

Author-supplied keywords

  • Allergic asthma
  • immunoglobulin E
  • omalizumab
  • persistency
  • response

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free